{"title":"anddexanet alfa是发生颅内出血的患者的Xa因子抑制剂的有效逆转剂","authors":"J. Friedli","doi":"10.22237/CRP/1567555500","DOIUrl":null,"url":null,"abstract":"<p>A critical appraisal and clinical application of Connolly SJ, Milling TJ, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. <em>N Engl J Med</em>. 2016;375(12):1131-1141. doi: <a href=\"https://doi.org/10.1056/NEJMoa1607887\">10.1056/NEJMoa1607887</a>.</p>","PeriodicalId":10422,"journal":{"name":"Clinical Research In Practice: The Journal of Team Hippocrates","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Andexanet alfa is an effective reversal agent for factor Xa inhibitors in patients that develop intracranial hemorrhage\",\"authors\":\"J. Friedli\",\"doi\":\"10.22237/CRP/1567555500\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>A critical appraisal and clinical application of Connolly SJ, Milling TJ, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. <em>N Engl J Med</em>. 2016;375(12):1131-1141. doi: <a href=\\\"https://doi.org/10.1056/NEJMoa1607887\\\">10.1056/NEJMoa1607887</a>.</p>\",\"PeriodicalId\":10422,\"journal\":{\"name\":\"Clinical Research In Practice: The Journal of Team Hippocrates\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-09-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Research In Practice: The Journal of Team Hippocrates\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22237/CRP/1567555500\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Research In Practice: The Journal of Team Hippocrates","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22237/CRP/1567555500","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Andexanet alfa is an effective reversal agent for factor Xa inhibitors in patients that develop intracranial hemorrhage
A critical appraisal and clinical application of Connolly SJ, Milling TJ, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375(12):1131-1141. doi: 10.1056/NEJMoa1607887.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
